Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

2020169 citationsJournal Articlehybrid Open Access

Authors

Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS. Pfizer Inc (NCT00721409).

Good health and well-being

Published in: Breast Cancer Research and Treatment

Volume 183, Issue 2, pp. 419-428

Field-Weighted Citation Impact: 9.38